<DOC>
	<DOCNO>NCT02150070</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics ( PK ) intravenous ( IV ) administration ASP2408 manufacture new production clone also follow single ascend dos subcutaneous ( SC ) injection clinical trial material .</brief_summary>
	<brief_title>A Study Evaluate Single Intravenous ( IV ) Dose Using New Manufactured Clone Single Ascending Doses Subcutaneous ( SC ) Injections</brief_title>
	<detailed_description>The four dos study sequential cohort 8 subject , start IV dose , follow subcutaneous dos ascend order dose . Within cohort , subject randomize either active drug match placebo 3:1 ratio ( 6 active 2 placebo ) . All subject arm confine 8 day follow minimum 90 day 9 month necessary . Subjects study drug terminate remain study , possible scheduled procedure follow-up . Subjects detectable blood level ASP2408 Day 90 unblinded follow monthly ASP2408 level limit quantification . In addition , subject persistent anti-ASP2408 antibody Day 90 unblinded follow every 30 ( ± 3 ) day 9 month level antibody decline , longer detectable , and/or clinical consequence .</detailed_description>
	<criteria>The subject weigh least 50 kg , maximum 92.5 kg body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive The subject 's 12lead electrocardiogram ( ECG ) result normal The female subject must least two year postmenopausal OR surgically sterile pregnant lactate The male subject agree use male condom end study 60 day post dose , whichever long The subject history clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy exclude adequatelytreated nonmelanoma skin cancer The subject history severe allergic anaphylactic reaction The subject female childbearing potential The subject history consume 14 unit alcoholic beverage per week history alcoholism drug/chemical/substance abuse within past 2 year ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) The subject positive test alcohol drug abuse The subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic checkin The subject past history opportunistic infection The subject supine mean systolic blood pressure &lt; 90 &gt; 160 mmHg mean diastolic blood pressure &lt; 50 &gt; 90 mmHg , mean pulse rate high 100 beat per minute ( bpm ) The subject know positive human immunodeficiency virus ( HIV ) antibody The subject positive tuberculosis ( TB ) skin test , Quantiferon Gold test TSPOT® test The subject positive test hepatitis C antibody , positive test hepatitis B surface antigen ( HBsAg ) , positive hepatitis B core antibody Subject 's alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) value great 1.5 time upper limit normal Subject 's laboratory test result outside normal limit consider clinically significant The subject receive vaccine within 60 day prior study drug administration The subject receive systemic immunosuppressant agent within 2 month prior study drug administration The subject previously receive antibody therapeutic biologic product prior study drug administration The subject receive systemic steroid within 2 month steroid inhaler within 1 month prior study drug administration The subject treatment prescription , nonprescription complementary alternative medicine ( CAM ) within 14 day prior study drug administration exception stable hormone replacement therapy ( HRT ) and/or intermittent acetaminophen ( maximum 2 g/day ) The subject receive experimental agent within 30 day five halflives , whichever longer , prior study drug administration The subject participate another clinical trial participate another dose group current trial The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission The subject condition precludes subject 's participation trial The subject history heavy smoking use tobaccocontaining product nicotine nicotinecontaining product past six month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>ASP2408</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Safety Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>